Leader in the Precision Oncology Field

We are committed to improving the standards of cancer patient care  and advancing precision oncology through our NGS technology.

Our Mission & Vision

Our Mission: Guard Life via Science.
Our Vision: To Become a New Pillar in the International Healthcare Industry.

A Global Perspective

Having headquarters and laboratories in both the United States and China, we can run our operation with a global vision and support our partners to initiate clinical trials that incorporate a larger segment of the global patient population.

Improving Cancer Patients’

Quality of Life Globally

Through Genomic Testing

Cancer is one of the major public health problems faced by humanity. It not only brings a threat to human health, but also causes a heavy burden on economic and social development.

Burning Rock believes that genomic testing provides clinicians with tools to make a more precise decision on cancer treatment selection; therefore, increasing genomic testing has a profound impact on fighting against cancer.

We are committed to developing advanced molecular biology and data science technologies to provide more effective, accurate, and affordable tests to transform cancer treatment and improve cancer patients'quality of lives.

Why Partner with Burning Rock?

Burning Rock is the industry leader for NGS precision oncology testing in China, with one-third overall market share and 80% in-hospital market share**An industry report by China Insights Consultancy.

Value and Accessibility

We provide molecular genetic testing at an affordable price for all cancer patients, research institutes and healthcare systems in the world so everyone has access to the most technically advanced care possible.

World Class Performance

In the FDA study of 8 leading NGS oncology panel vendors, Burning Rock's testing is among the best in Sensitivity and LoD  and  first in the ctDNA Panel comparison* *Gong B, Li D, Kusko R, et al. Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. Genome Biol. 2021;22(1):109. Published 2021 Apr 16. doi:10.1186/s13059-021-02315-0
*Deveson IW, Gong B, Lai K, et al. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 2021;39(9):1115-1128. doi:10.1038/s41587-021-00857-z

Custom Assays

Burning Rock offers custom assays from RUO to IVD that fit for validation of novel applications, including RNA Seq, WES, digital pathology, and MRD.

Tissue and Liquid Biopsy

We offer flexibility in either tissue or liquid panel testing; however, we emphasize the advantages of a complementary test for concordance check to improve differentiation between germline and somatic mutations, which is essential for certain hereditary cancers.

Global Trial Capability

Burning Rock supports our partners in global trials with a CLIA/CAP laboratory in both the United States and China. And, our vast international regulatory experience in China, the United States, European Union, and Japan makes Burning Rock an expert on regulatory processes.